Immuneering’s (IMRX) Buy Rating Reiterated at Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $13.00 price objective on the stock.

IMRX has been the subject of several other research reports. Needham & Company LLC restated a “buy” rating and issued a $12.00 price target on shares of Immuneering in a research note on Friday. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $1.80 on Monday. The stock has a market capitalization of $55.89 million, a price-to-earnings ratio of -0.91 and a beta of -0.32. The firm’s 50 day simple moving average is $1.79 and its 200-day simple moving average is $2.00. Immuneering has a 12 month low of $1.00 and a 12 month high of $3.83.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16). Analysts anticipate that Immuneering will post -1.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immuneering

Large investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. acquired a new stake in shares of Immuneering in the fourth quarter worth approximately $390,000. First Manhattan CO. LLC. acquired a new stake in Immuneering during the 4th quarter worth $71,000. Bridgeway Capital Management LLC grew its holdings in shares of Immuneering by 77.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after buying an additional 22,400 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Immuneering in the fourth quarter valued at about $47,000. Finally, XTX Topco Ltd raised its position in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after buying an additional 20,871 shares during the last quarter. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.